Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2013

View Archived Issues

Celon Pharma characterizes novel FGFR inhibitor

Pharmacological and behavioral characterization of a murine model of chronic migraine

Bioinformatics screening identifies antidepressant drugs that have anticancer potential

LEO Pharma commits to increasing transparency of clinical trial data

Atheris and Debiopharm Group to collaborate on lead optimization for oncolytic venom peptide

Evotec achieves first milestones in immunology collaboration with UCB

Preclinical and first clinical data presented for GS-5737

Prevenar 13 launched in Japan

Cells of a patient with Unverricht-Lundborg disease corrected for splice defect

Rigel provides update on two pipeline candidates

FDA advisory committee votes in favor of sofosbuvir for chronic HCV

Kyowa Hakko Kirin updates activities of third quarter 2013

Boehringer Ingelheim Pharma discloses new HCMV DNA polymerase inhibitors

AstraZeneca synthesizes novel beta-lactamase inhibitors for bacterial infections

Columbia University prepares new ferroptosis modulators

LabCorp launches FDA-approved companion diagnostic for colorectal cancer

Amgen divulges novel PI3Kdelta inhibitors

Amorfix Life Sciences detects misfolded SOD1 in sporadic ALS

Actelion receives positive CHMP opinion for Opsumit in PAH

Synflorix receives positive opinion from the EMA's CHMP for additional indication

Novel SYK inhibitor HM-0523 proves effective as antiarthritic drug in preclinical models

Mologen files application in Belgium to conduct trial in small cell lung cancer

Cimzia gets positive opinion for PsA and approval for severe active axial spondyloarthritis

FDA extends approval of Lundbeck's Sabril

Vaccine targeting IDO safe and well tolerated in first-in-human study

Pulmatrix reports completion of first part of phase Ib study of PUR-0200 in COPD

Milestone Pharmaceuticals begins phase I trial of MSP-2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...